Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MLLT11
REST API REST API
Homo sapiens
MLLT11 is differentially expressed in 303 experiments: 158 organism parts: liver, bone marrow, ... (156 more);, 226 disease states: normal, prostate carcinoma, ... (224 more);, 105 cell types 502 cell lines 36 compound treatments and 71 other conditions.
Synonyms AF1Q
Orthologs AF1Q_BOVIN (Bos taurus)   mllt11 (Danio rerio)   Mllt11 (Mus musculus)   Mllt11 (Rattus norvegicus)   mllt11 (Xenopus laevis)   MLLT11 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term positive regulation of apoptosis, molecular_function, cellular_component, positive regulation of transcription, DNA-dependent, positive regulation of mitochondrial depolarization, positive regulation of release of cytochrome c from mitochondria
UniProt Accession Q13015, Q6FGF7
Search EB-eye ENSG00000213190
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, ... (44 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
A549
2
E-GEOD-6013, E-GEOD-3202
DU145
2
E-GEOD-20089, E-GEOD-17482
496 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-21750, E-GEOD-2822, ... (50 experiments)

Factor Value U/D Experiments
2
E-TABM-130, E-TABM-145
monocyte
2
E-GEOD-11755, E-MEXP-583
spheroid recovery
1
E-GEOD-4219
CD11c+ dendritic cell
1
E-MEXP-1600
monocyte-derived osteoclast
1
E-MEXP-2019
CD34+
1
E-AFMX-5
99 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-TABM-15, E-MEXP-2280, ... (62 experiments)

Factor Value U/D Experiments
prostate carcinoma
4
E-GEOD-96, E-MEXP-2034, E-MTAB-62, E-MTAB-37
glioblastoma
3
E-MTAB-62, E-GEOD-4290, E-MTAB-37
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
myeloma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
rhabdomyosarcoma
2
E-MTAB-62, E-MTAB-37
220 more value(s).


Compound treatment

studied in E-GEOD-5681, E-GEOD-5741, E-GEOD-5542, E-GEOD-3720, E-GEOD-5824, ... (23 experiments)

Factor Value U/D Experiments
none
2
7
E-GEOD-5824, E-MEXP-1958, E-TABM-868, E-MEXP-1601, E-GEOD-7307, ... (9 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
non-targeting
1
E-MEXP-2218
filtered air
1
E-TABM-127
hydrogen peroxide
1
E-GEOD-5339
CXCL4
1
E-GEOD-20484
30 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
32 years
1
E-GEOD-4922
32
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-2034, ... (12 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-GEOD-4667, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-MEXP-2280, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-2152, E-MEXP-1437, E-TABM-1029, E-MEXP-1996, E-GEOD-17476, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-MEXP-2657, E-GEOD-12773, E-TABM-127, E-GEOD-20540, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-MEXP-1412, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

Qpcr egfr dct
studied in E-GEOD-5851

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-1703, E-GEOD-12438, E-MEXP-1509, E-MEXP-548, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-MEXP-70, E-GEOD-17400 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-4922

Processing time: 0.269 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM